☆ 4.5 Article

Optimum selection criteria for secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer: A multicenter study from the Gynecologic Oncology Research Investigators coLLaborAtion group (GORILLA-3001)

JOURNAL OF SURGICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Oncology

Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis

Min-Hyun Baek et al.

Summary: This study focused on evaluating the survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. The findings indicated that complete cytoreductions were associated with better survival outcomes and that maximal tumor resection significantly increased overall survival in this patient population.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

Joo-Hyuk Son et al.

Summary: This study evaluated the clinical characteristics of 262 patients with recurrent ovarian cancer to identify factors associated with the selection of patients who would benefit from secondary cytoreductive surgery (SCS). The study found that patients who received SCS had significantly longer median survival compared to those who received chemotherapy alone. Limited regional recurrence emerged as a simplified factor for predicting no residual disease after SCS.

CANCERS (2022)

Add to Collection

Review Oncology

The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis

Claudia Marchetti et al.

Summary: This study compared secondary cytoreductive surgery followed by systemic therapy with systemic therapy alone for recurrent ovarian cancer patients. The results showed that secondary cytoreductive surgery was associated with significantly better progression-free survival (PFS) improvement, especially for the complete resection subpopulation. Overall survival (OS) was similar between the groups, but favored the complete resection subpopulation.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

P. Harter et al.

Summary: The study demonstrates that in patients with recurrent ovarian cancer, secondary cytoreductive surgery followed by chemotherapy results in longer overall survival compared to chemotherapy alone. Quality of life measures did not differ significantly between the two treatment groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

Tingyan Shi et al.

Summary: In patients with platinum-sensitive relapsed ovarian cancer, secondary cytoreduction followed by chemotherapy significantly prolongs progression-free survival compared to chemotherapy alone. Patients should be informed about the option of secondary cytoreduction in specialized centers.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.

Andreas Du Bois et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Reproductive Biology

Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer

Szymon Piatek et al.

JOURNAL OF OVARIAN RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

Robert L. Coleman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer

Giorgio Bogani et al.

JOURNAL OF GYNECOLOGIC ONCOLOGY (2018)

Add to Collection

Article Oncology

A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer

Renee A. Cowan et al.

GYNECOLOGIC ONCOLOGY (2017)

Add to Collection

Article Oncology

Surgery for Recurrent Epithelial Ovarian Cancer in the Netherlands A Population-Based Cohort Study

Rafli van de Laar et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)

Add to Collection

Article Oncology

Positron Emission Tomography-Laparoscopy Based Method in the Prediction of Complete Cytoreduction in Platinum-Sensitive Recurrent Ovarian Cancer

Francesco Fanfani et al.

ANNALS OF SURGICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection

Wen-Juan Tian et al.

ANNALS OF SURGICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO

Philipp Harter et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)

Add to Collection

Editorial Material Oncology

CA 125 and the Detection of Recurrent Ovarian Cancer

Robert C. Bast

CANCER (2010)

Add to Collection

Review Oncology

Treatment for Recurrent Ovarian Cancer-At First Relapse

Kimio Ushijima

JOURNAL OF ONCOLOGY (2010)

Add to Collection

Review Oncology

Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis

Robert E. Bristow et al.

GYNECOLOGIC ONCOLOGY (2009)

Add to Collection

Article Oncology

Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

Philipp Harter et al.

ANNALS OF SURGICAL ONCOLOGY (2006)

Add to Collection

Article Oncology

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

DS Chi et al.

CANCER (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.